Format

Send to

Choose Destination
Virology. 2007 Mar 30;360(1):36-49. Epub 2006 Nov 13.

Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates.

Author information

1
Wyeth Vaccines Research, 401 N. Middletown Road, Pearl River, NY 10965, USA. johnsoe1@wyeth.com

Abstract

Although vesicular stomatitis virus (VSV) neurovirulence and pathogenicity in rodents have been well studied, little is known about VSV pathogenicity in non-human primates. To address this question, we measured VSV viremia, shedding, and neurovirulence in macaques. Following intranasal inoculation, macaques shed minimal recombinant VSV (rVSV) in nasal washes for 1 day post-inoculation; viremia was not detected. Following intranasal inoculation of macaques, wild type (wt) VSV, rVSV, and two rVSV-HIV vectors showed no evidence of spread to CNS tissues. However, macaques inoculated intrathalamically with wt VSV developed severe neurological disease. One of four macaques receiving rVSV developed clinical and histological signs similar to the wt group, while the remaining three macaques in this group and all of the macaques in the rVSV-HIV vector groups showed no clinical signs of disease and reduced severity of histopathology compared to the wt group. The implications of these findings for rVSV vaccine development are discussed.

PMID:
17098273
PMCID:
PMC1865117
DOI:
10.1016/j.virol.2006.10.026
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center